What has FDA cited under 21 CFR 211.67(a)?

1 DSRV article cite 21 CFR 211.67(a). Enforcement cases behind them: FDA Warning Letter 320-26-40 to Cohance Lifesciences Limited, January 30, 2026, citing the firm's Hyderabad finished-dose facility under 21 CFR 211.192 and 21 CFR 211.67(a). Inspection exposure across them: 1 high.

What does DSRV recommend for 21 CFR 211.67(a)?

From the newest article (Your Complaint Investigation Is Closed. FDA Says the Risk Is Not.): The decisive control is a procedural handoff that forces a shared-equipment complaint to trigger a cleaning data review and a multi-product impact assessment, rather than leaving that connection to individual investigator judgment. DSRV is decision support, not legal advice; verify against the official source each article names.

Browse by regulation1 article · 1 high

21 CFR 211.67(a)

Every DSRV article whose Regulatory Snapshot cites 21 CFR 211.67(a): the enforcement case behind it, the inspection exposure it created, and what the desk would do about it.

Inspection exposure across the set

What has FDA cited under 21 CFR 211.67(a)?: 1 DSRV article cite 21 CFR 211.67(a). Enforcement cases behind them: FDA Warning Letter 320-26-40 to Cohance Lifesciences Limited, January 30, 2026, citing the firm's Hyderabad finished-dose facility under 21 CFR 211.192 and 21 CFR 211.67(a). Inspection exposure across them: 1 high.
What does DSRV recommend for 21 CFR 211.67(a)?: From the newest article (Your Complaint Investigation Is Closed. FDA Says the Risk Is Not.): The decisive control is a procedural handoff that forces a shared-equipment complaint to trigger a cleaning data review and a multi-product impact assessment, rather than leaving that connection to individual investigator judgment. DSRV is decision support, not legal advice; verify against the official source each article names.

May 20267 min readHigh exposurecited as a tag
Your Complaint Investigation Is Closed. FDA Says the Risk Is Not.
FDA's January 2026 warning letter to Cohance Lifesciences rejected a re-opened complaint investigation for the same gap it had the first time. The enforcement record documents what happens when a quality unit treats complaint handling and cleaning validation as separate systems.
Case
FDA Warning Letter 320-26-40 to Cohance Lifesciences Limited, January 30, 2026, citing the firm's Hyderabad finished-dose facility under 21 CFR 211.192 and 21 CFR 211.67(a).
DSRV take
The decisive control is a procedural handoff that forces a shared-equipment complaint to trigger a cleaning data review and a multi-product impact assessment, rather than leaving that connection to individual investigator judgment.

Address this risk

Pressure-test your evidence before an inspector reads it

Bring the document that has to hold up under 21 CFR 211.67(a). DSRV maps the evidence, names the gaps, and routes judgment calls to human review. Controlled intake, no public file upload.

Apply for the Stability Pilot Ask The Vault about 21 CFR 211.67(a)

Regulatory intelligence and interpretation, not legal advice. Verify against the official FDA or ICH source each article names.